RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer

Pancreatic Cancer Clinical Trial

Official title:

Phase II Study of RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00409292
• Other study ID #: 06-197
• Status: Completed
• Phase: Phase 2
• First received: December 6, 2006
• Last updated: July 23, 2014
• Start date: January 2007
• Est. completion date: May 2009

Study information

• Verified date: July 2014
• Source: Dana-Farber Cancer Institute
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this research study is to investigate if RAD001 is an effective treatment for pancreatic cancer that has spread and not responded to treatment. Experiments have shown that RAD001 can prevent cells from multiplying. RAD002 has also been tested in laboratory experiments imitating cancer conditions and the results have been promising.

Description:

• Participants taking part in this research study will be given a study medication-dosing calendar for each treatment cycle. Each cycle lasts four weeks during which you will be taking the study drug, RAD001, orally every day.

• Participants will come into the clinic every other week during the time of enrollment. At each clinic visit blood work will be taken to monitor the participants health and a physical exam will be performed. CT scans will be repeated every 2 months to assess the tumor.

• Participants will remain on the study as long as they continue to benefit from the study medication.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 33
• Est. completion date: May 2009
• Est. primary completion date: January 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Pathologic confirmation of pancreatic adenocarcinoma

• 18 years of age or older

• At least one measurable site of disease according to RECIST criteria that has not been previously irradiated. If patient has had previous radiation to the marker lesion(s), there must be evidence of progression since the radiation.

• Treated with gemcitabine-based chemotherapy with documented tumor progression on gemcitabine or intolerance to gemcitabine.

• Prior treatment with no more than 1 prior chemotherapy regimen for metastatic disease.

• Minimum of two weeks since any major surgery, completion of radiation, or completion of all prior systemic anti-cancer therapy.

• ECOG performance status 0-1.

• Life expectancy of greater than 12 weeks.

• Adequate bone marrow and liver function.

• Must be able to swallow tablets.

Exclusion Criteria:

• Prior treatment with an investigational drug within the preceding 4 weeks.

• Prior treatment with an inhibitor of mTOR

• Chronic treatment with systemic steroids or another immunosuppressive agent

• More than one prior chemotherapy treatment for metastatic disease

• Uncontrolled brain or leptomeningeal metastases, including patient who continue to require glucocorticoids for brain or leptomeningeal metastases.

• Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin

• Patients with chronic renal insufficiency

• Other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study.

• Known history of HIV seropositivity

• Impairment of gastrointestinal function or gastrointestinal disease that my significantly alter the absorption of RAD001.

• Active, bleeding diathesis or an oral vitamin K antagonist medication

• Women who are pregnant or breast feeding

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Pancreatic Cancer
• Pancreatic Neoplasms

Intervention

Drug:
• RAD001
Taken orally daily for as long as the participant continues to receive a benefit.

Locations

Country	Name	City	State
United States	Beth Israel Deaconess Medical Center	Boston	Massachusetts
United States	Dana-Farber Cancer Institute	Boston	Massachusetts
United States	Massachusetts General Hospital	Boston	Massachusetts

Sponsors (4)

Lead Sponsor	Collaborator
Dana-Farber Cancer Institute	Beth Israel Deaconess Medical Center, Massachusetts General Hospital, Novartis

Country where clinical trial is conducted

United States, 

References & Publications (1)

Wolpin BM, Hezel AF, Abrams T, Blaszkowsky LS, Meyerhardt JA, Chan JA, Enzinger PC, Allen B, Clark JW, Ryan DP, Fuchs CS. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol. 2009 Jan 10;27(2): — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To Assess Progression-free Survival of RAD001 at Two Months in Patients With Metastatic Pancreatic Cancer Whose Disease Has Progressed on Gemcitabine Chemotherapy.	The Outcome Measure is reporting the number of participants experiencing Progression-free Survival at 2 months after treatment.; The study was designed with a primary end point of progression-free survival (PFS), defined as the time from study entry to documentation of progressive disease or death from any cause. On the basis of prior studies of second-line treatment in metastatic pancreatic cancer, we estimated that such treatment has been associated with a median PFS of 2 months. Our study design used a one-stage design with a target accrual of 35 eligible patients, with the assumption that an improvement in PFS at 2 months from 50% to 71% would warrant further study in this patient population.	two months	No
Secondary	To Assess the Safety of RAD001 in Patients With Metastatic Pancreatic Cancer	Patients were followed for the duration of their time on treatment and 30 days after their last dose of RAD001. The number of patients with treatment-related adverse events are reported.	Patients were followed for the duration of their time on treatment and 30 days after their last dose of RAD001.	Yes
Secondary	to Assess Response Rate Associated With RAD001 in This Patient Population.	The secondary objectives of the study were to assess tumor response rate and overall survival. Patients were required to have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST). Per RECIST, for target lesions assessed by CT: Complete Response (CR) is Disappearance of all target lesions; Partial Response (PR) is >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) equals CR + PR.	2 years	No
Secondary	to Assess Overall Survival Associated With RAD001 in This Patient Population.	Overall survival was defined as the time from study entry until death from any cause.	2 years	No